Latest news
Nanjing Leads Biolabs Co., Ltd. Advances Opamtistomig (Pd-L1/4-1Bb Bispecific Antibody) to Expansion Phase in First-Line Hepatocellular Carcinoma Clinical Study - marketscreener.commarketscreener.com · Thu, 06 Aug 2026 10:52:26 GMTNanjing Leads Biolabs Advances Key Liver Cancer Trial for Opamtistomig - TipRanksTipRanks · Thu, 06 Aug 2026 09:52:49 GMTLeads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Hepatocellular Carcinoma Following Positive Efficacy Signals - The Manila TimesThe Manila Times · Thu, 06 Aug 2026 01:13:02 GMTLeads Biolabs Wins IND Approval to Test Opamtistomig in Metastatic Colorectal Cancer - BioPharm InternationalBioPharm International · Wed, 05 Aug 2026 19:39:16 GMTLeads Biolabs' PD-L1/4-1BB Bispecific Antibody IND Application for Combination Therapy in Metastatic Colorectal Cancer Approved, Further Strengthening Gastrointestinal Oncology Franchise - The Manila TimesThe Manila Times · Mon, 03 Aug 2026 03:56:06 GMTNanjing Leads Biolabs Completes Phase II Enrollment for Opamtistomig in Biliary Tract Cancer - TipRanksTipRanks · Sun, 02 Aug 2026 23:56:07 GMTLeads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Completes Patient Enrollment in Phase II Study for Biliary Tract Cancer, Further Demonstrating Breakthrough Potential in Immune-Cold Tumors - The Manila TimesThe Manila Times · Thu, 30 Jul 2026 10:40:18 GMT